Subject: Pact Is Signed With Sandoz To Study AIDS Compounds
Date: Published: 4/13/89 (28 lines)
Source:  Wall Street Journal.  Copyright Dow Jones & Co. Inc. 

    Technology Brief -- Repligen Corp.:  
    Pact Is Signed With Sandoz
    To Study AIDS Compounds

    Repligen Corp., Cambridge, Mass., and Sandoz Ltd., Basel,
 Switzerland, signed a two-year research and development
 agreement to develop therapeutic compounds effective against
 the HIV virus that causes AIDS. 
    Under the agreement, which may be extended, Sandoz, a
 chemical and pharmaceutical concern, will provide funding to
 Repligen, a biotechnology concern, for development of certain
 HIV proteins that will inhibit replication of the acquired
 immune deficiency syndrome virus.
    Repligen said payments will be made by Sandoz when
 specific predetermined scientific and clinical goals have
 been achieved.  Sandoz will retain manufacturing and marketing
 rights to products developed through the collaboration and
 Repligen will receive royalties on product sales, Repligen
 said.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]